| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8222260 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 8 Pages |
Abstract
Erlotinib can be safely administered with adjuvant IMRT-based CRT and chemotherapy. The efficacy of this regimen appears comparable to that of existing adjuvant regimens. Radiation Therapy Oncology Group 0848 will ultimately determine whether erlotinib produces a survival benefit in patients with resected pancreatic cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Joseph M. MD, MSc, Katherine Y. BS, Aaron T. BA, Amy MS, PA-C, Laura D. MD, PhD, Amanda L. ScM, Susannah MD, Lei MD, Dung T. MD, Ana MD, Manuel MD, PhD, Ross C. MD, Richard D. MD, MBA, Barish H. MD, Michael A. MD, Ralph H. MD, Timothy M. MD, MPH, PhD,